145 related articles for article (PubMed ID: 20632895)
1. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention.
Annemans L; Wittrup-Jensen K; Bueno H
J Med Econ; 2010; 13(3):418-27. PubMed ID: 20632895
[TBL] [Abstract][Full Text] [Related]
2. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
3. Aspirin for primary prevention: do potential benefits outweigh the risks?
Shakib S
Intern Med J; 2009 Jun; 39(6):401-7. PubMed ID: 19580619
[TBL] [Abstract][Full Text] [Related]
4. Potential economic impact of increasing low dose aspirin usage on CVD in the US.
Manson SC; Benedict A; Pan F; Wittrup-Jensen KU; Fendrick AM
Curr Med Res Opin; 2010 Oct; 26(10):2365-73. PubMed ID: 20738228
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
6. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
Noubiap JJ; Nansseu JR
Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
[TBL] [Abstract][Full Text] [Related]
7. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
[TBL] [Abstract][Full Text] [Related]
9. Aspirin overprescription in primary cardiovascular prevention.
Manes C; Giacci L; Sciartilli A; D'Alleva A; De Caterina R
Thromb Res; 2006; 118(4):471-7. PubMed ID: 16321425
[TBL] [Abstract][Full Text] [Related]
10. A health-economic evaluation of aspirin: primary prevention and cardiovascular disease.
Sakai T; Saku K
Intern Med; 2007; 46(8):431-3. PubMed ID: 17443030
[No Abstract] [Full Text] [Related]
11. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
Waltering A; Hemkens L; Florack C
Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
[TBL] [Abstract][Full Text] [Related]
12. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
Lamotte M; Piñol C; Brotons C; Annemans L; Guardiola E; Evers T; Kubin M
Rev Esp Cardiol; 2006 Aug; 59(8):807-15. PubMed ID: 16938230
[TBL] [Abstract][Full Text] [Related]
13. Aspirin in primary prevention: sex and baseline risk matter.
Algra A; Greving JP
Lancet; 2009 May; 373(9678):1821-2. PubMed ID: 19482200
[No Abstract] [Full Text] [Related]
14. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
15. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
Rodondi N; Bauer DC
Am J Med; 2004 Oct; 117(7):528-30. PubMed ID: 15464713
[No Abstract] [Full Text] [Related]
16. [Polish forum for prevention guidelines on cardiovascular risk assessment].
Podolec P; Kopeć G; Pajak A; Undas A; Kozek E; Tykarski A; Naruszewicz M; Stańczyk J; Opala G; Godycki-Cwirko M; Rynkiewicz A; Torbicki A; Musiał J
Kardiol Pol; 2007 Jan; 65(1):100-4. PubMed ID: 17295170
[No Abstract] [Full Text] [Related]
17. [The role of aspirin in the primary prevention of cardiovascular disease].
Rodondi N; Cornuz J
Rev Med Suisse; 2006 Mar; 2(56):646-51. PubMed ID: 16597054
[TBL] [Abstract][Full Text] [Related]
18. Aspirin in the primary prevention of cardiovascular disease.
Galloway CF; Stevenson JC
Maturitas; 2011 Jan; 68(1):3-4. PubMed ID: 21111550
[No Abstract] [Full Text] [Related]
19. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
Franco OH; der Kinderen AJ; De Laet C; Peeters A; Bonneux L
Int J Technol Assess Health Care; 2007; 23(1):71-9. PubMed ID: 17234019
[TBL] [Abstract][Full Text] [Related]
20. Cost and effectiveness of cardiovascular prevention.
Boyar A
Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
[No Abstract] [Full Text] [Related]
[Next] [New Search]
